Diazolin

Quick links to important sections

Diazolin

Selected form

Method of action: Antiallergic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diazolin

Property Description
Active Ingredient Mebhydrolin (INN)
Form Dragee or Tablet (Oral Application)
Pharmacological Class First-Generation Antihistamine
Mechanism Group H1-Histamine Receptor Blocker
Origin Synthetic Compound

What Type of Medicine is Diazolin (Mebhydrolin)?

Diazolin is the established trade designation for a pharmaceutical product whose single active therapeutic agent is Mebhydrolin, which functions as an H1-histamine receptor blocker. This agent belongs to the class of first-generation antihistamines.

The core identity of Diazolin is defined by its action as an antagonist that prevents histamine, a substance the body naturally releases during allergic reactions, from binding to the H1 receptors on various cells. Mebhydrolin is a synthetic compound, chemically identified as Mebhydrolin napadisilate, and is classified within the R06AX group of other antihistamines for systemic use. Its position as a first-generation agent is recognized for its ability to cross the blood-brain barrier, a distinguishing property that often leads to central effects, which are documented in pharmacological studies of this class. This means the medicine works by blocking specific chemical reactions in the body and may cause drowsiness.


Composition, Form, and General Purpose

The medication contains the active ingredient in its stable salt form, Mebhydrolin napadisilate, confirmed as a single-ingredient product based on its International Nonproprietary Name (INN) status. This formulation is most commonly provided for oral application as a solid dosage form, typically a dragee or a tablet. The dragee form, often marketed for its ease of swallowing and stable coating, is a key distinguishing feature of the Diazolin brand.

The purpose of this chemical structure and form is to enable the systemic delivery of the active agent to reach histamine receptors throughout the body. By effectively acting as an H1-histamine receptor antagonist, the general purpose of Diazolin is to modulate the body's response to histamine, offering general relief from the uncomfortable physical manifestations often associated with hypersensitivity reactions. Mebhydrolin's systemic use is primarily intended for the palliative management of various allergic manifestations. In simple terms, the drug is used to help ease the physical symptoms that occur during an allergic reaction, such as generalized itching or a persistent rash.

What side effects are possible with Diazolin?

Possible Side Effects and Safety Information

The official safety profile for Diazolin (Mebhydrolin) is classified by the type and frequency of adverse reactions, consistent with regulatory standards for first-generation antihistamines.

Adverse Reactions Classified by System and Frequency

System-Organ Class Common Side Effects Less Common/Rare Effects
Nervous System Disorders Drowsiness, Sedation Dizziness, Paresthesia, Anxiety (paradoxical excitability in children)
Gastrointestinal Disorders Dry Mouth, Gastrointestinal Irritation (nausea, heartburn) Vomiting, Constipation
Renal and Urinary Disorders Urinary retention (difficulty passing urine)

The most frequently reported effects are drowsiness and sedation, categorized as common due to the drug’s properties. These effects may impact activities requiring full mental alertness. Less common side effects are linked to anticholinergic activity, including blurred vision and difficulty urinating.

Serious and Population-Specific Safety Statements

Official regulatory documents note that very rare but serious adverse reactions may involve the blood and lymphatic system, including conditions such as agranulocytosis (a severe drop in white blood cells). The potential for severe hypersensitivity reactions is also documented.

Safety considerations vary by age group. In children, the drug may paradoxically cause excitability and sleep disturbances, rather than sedation. Older adults may be more susceptible to central nervous system effects like confusion and peripheral effects such as urinary retention. Use during pregnancy and breastfeeding is generally not recommended, as per prescribing information.

Overdose and Emergency Response

The official regulatory profile for an overdose of Diazolin (Mebhydrolin) focuses on serious manifestations arising from its action as a first-generation antihistamine. Documented clinical signs primarily affect the Central Nervous System (CNS), ranging from states of excitation, such as seizures, ataxia, and hallucinations, to profound CNS depression potentially leading to coma. Other documented signs of toxicity include manifestations of anticholinergic syndrome, notably tachycardia (rapid heart rate), mydriasis (dilated pupils), and dry mouth. Official labeling notes that pediatric patients are at an increased risk for severe CNS excitation in overdose scenarios.

Overdose is classified by regulatory authorities as potentially severe due to the risk of life-threatening systemic outcomes, including respiratory depression and cardiovascular collapse. Due to the severity of these potential complications, the guidance mandates that patients seek immediate medical attention for any suspected overdosage. Contacting emergency services immediately is required upon the appearance of severe symptoms like difficulty breathing or unresponsiveness. Management of an overdose is restricted to symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known. Hospital monitoring, including ECG monitoring, may be required, and procedures such as gastric decontamination may be employed.

Therapeutic Uses of Diazolin

Based on its classification and purpose as a systemic anti-allergic agent, Diazolin is applied across therapeutic domains where additional symptomatic support is needed, primarily addressing conditions related to hypersensitivity reactions. The therapeutic use is applicable within clinical settings where it is relevant for easing symptoms in conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria.

The medication is used in situations involving conditions such as hay fever, seasonal or perennial allergic rhinitis, and various forms of allergic dermatoses and hives. Diazolin is relevant for easing symptom clusters that may become intense or disruptive, including manifestations such as widespread pruritus (itching) and a persistent runny nose. Applied during phases of increased distress or discomfort, it is commonly used to help with supportive relief when these symptoms interfere with routine activities. “It is applied when symptoms create noticeable functional strain, such as intense itching or persistent nasal discharge.”


Quick Fact: Pruritus and Hives Diazolin is applied across domains where symptoms like intense itching and sudden allergic rashes are present. This supportive use may assist with easing the overall symptom burden, and generally supports the patient during symptomatic periods.

Regulatory References

  1. Mebhydrolin H1-Antihistamine Action overview from the NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Diazolin?

The official eligibility for Diazolin (Mebhydrolin) is strictly defined by regulatory documents based on a patient’s pre-existing conditions and physiological state. Use is generally permitted for adults and children who meet the minimum approved age threshold, typically starting at 3 years old. However, newborns and infants are explicitly prohibited from use.


Absolute Contraindications (Must Not Use)

Diazolin is formally contraindicated and must not be used in patients with specific comorbidities, including:

  • Prostatic hyperplasia or Pyloric stenosis
  • Closed-angle glaucoma
  • Gastric or duodenal ulcers and inflammatory diseases of the gastrointestinal tract
  • Diagnosed Epilepsy, specific cardiac arrhythmias, and Porphyria
  • Known hypersensitivity to the active substance or excipients

Restrictions and Special Populations

Regulatory warnings indicate that use during pregnancy is not recommended. Furthermore, breastfeeding should be discontinued during administration. Conditional use is mandated for patients with hepatic insufficiency or renal insufficiency, requiring special consideration and potential adjustment.

What should I know about interactions with other medicines?

The interaction profile for Diazolin (Mebhydrolin) defines specific co-administration restrictions and pharmacokinetic alterations documented in official regulatory sources.

Interacting Category Regulatory Description
MAO Inhibitors (MAOIs) Co-administration is restricted as the combination may prolong and intensify anticholinergic effects.
CNS Depressants & Alcohol Results in an additive or potentiated sedative effect; the effects of ethanol are explicitly enhanced.
Anticholinergic Agents Concurrent use can prolong and intensify the anticholinergic effects of the medicine.

Metabolic and Administration Constraints Mebhydrolin is formally documented as an inducer of hepatic microsomal enzymes. This specific pharmacokinetic mechanism means that co-administered medicines that are substrates for these induced enzymes may experience reduced systemic exposure, potentially altering their effectiveness as documented in regulatory data.

Specific administration rules are in place: the tablet or dragee must be taken during or immediately after a meal.

Population-Specific Considerations Official regulatory documents advise formal caution for patients with hepatic or renal insufficiency. These populations may require dose adjustment due to the potential for altered clearance of Mebhydrolin, which could increase the severity of any interaction-related adverse effects.

Mechanism of Action

How Diazolin Works

Diazolin, whose active ingredient is mebhydrolin, is a first-generation antihistamine that exerts its pharmacological action by modulating signaling mediated by the inflammatory mediator histamine. It targets the H1 histamine receptor on both peripheral and central cells.


H1 Receptor Antagonism

Diazolin acts as a competitive antagonist at the H1 histamine receptor. By binding to the receptor, it structurally impedes the binding of endogenous histamine released by mast cells and basophils. This engagement with receptor-mediated signaling suppresses the initiation of histamine-driven intracellular effects, thus modulating excessive physiological responses, including those mediated by increased capillary permeability and non-vascular smooth muscle activation.


Central Pathway Modulation

In addition to peripheral receptor antagonism, the compound accesses central nervous system (CNS) pathways by crossing the blood-brain barrier. Interaction with central H1 receptors influences the neuronal pathways that regulate arousal, which constitutes a distinct pharmacodynamic effect independent of its peripheral mechanism.

Dosage and Administration Information

How to Use Diazolin: Official Administration Guidelines

Diazolin, which contains the substance Mebhydrolin napadisilate, is standardized for use as an oral medication. The official instructions for administration are structured around standardized dosing, frequency, and specific meal-timing requirements.


Administration Scope

Field Instruction
Route of administration Oral
Dosing schedule (Adults) Typically 100 mg to 300 mg total daily dose. Maximum labeled daily dose is up to 600 mg.
Timing in relation to meals Must be taken during or immediately after a meal.
Preparation requirements The dragee or tablet is intended to be swallowed whole without chewing. For young children, the tablet may be crushed and mixed with food.
Age-group rules Specific total daily dose ranges are defined for pediatric age groups (e.g., 2-5 years, 5-10 years). Dose adjustments or changes to dosing intervals may be required for patients with hepatic or renal impairment.
Missed-dose rules If a dose is missed, do not take a double dose to compensate; the next scheduled dose should be taken at the usual time.

Resulting Procedural Structure

The procedural structure for the use of Diazolin is defined by its oral administration and divided dose frequency:

  • Take the prescribed amount from the total daily dose regimen (50 mg or 100 mg strength).
  • Swallow the dose whole, or crush and mix with food if appropriate for the patient's age.
  • Administer the dose during a meal or immediately following a meal.
  • Repeat the procedure according to the assigned divided dose frequency (typically 1 to 3 times per day).

This protocol standardizes how the active agent is introduced systemically via the oral route. The requirement for a divided dose administered with or immediately after a meal defines the approach to maintaining consistent substance levels, ensuring adherence to the prescribed regimen.

Recent Clinical Evidence

Research evidence / Overview of studies

This section outlines the primary research that has summarized research related to Compound X and Condition A.


Core Efficacy and Symptom Management

The primary evidence for Compound X comes from its pivotal clinical trial program.

  • Pivotal Phase 3 Trials (Efficacy)

    • Two Phase 3 randomized, placebo-controlled trials reported a difference in the key symptom, Pain Score Y, when compared with placebo.
    • These studies also examined whether Compound X affected pain levels at the 72-hour assessment.
    • The primary endpoint analysis in the Phase 3 trials evaluated a change in symptom scores at the end of the 12-week study period.
  • Extended Use Data (Long-term)

    • Open-label extension studies evaluated the observed effects of Compound X over a period of up to two years.
    • These studies found that the observed changes in symptom scores remained consistent throughout the full duration of follow-up.

Safety and Tolerability Profile

The safety profile of Compound X was primarily established in Phase 1 and Phase 3 studies.

  • Pharmacokinetics and Hepatic Function

    • Phase 1 studies found no need for dose adjustments when evaluating patients with mild liver impairment.
    • The drug is primarily metabolized via the CYP2D6 pathway, and specific drug-drug interaction studies have investigated its potential effects when co-administered with moderate CYP2D6 inhibitors.
  • Overall Safety

    • The most commonly reported adverse events (AEs) in the clinical trials included gastrointestinal issues.
    • No new safety signals were identified in the long-term extension studies.
    • The combined data provide the basis for the safety findings.

Secondary Research Findings

Research has also explored the observed effects of Compound X in specific patient populations and in combination with other agents.

  • Quality of Life (QoL) Metrics

    • Research has explored QoL (Quality of Life) measures in relation to symptom management.
    • Secondary endpoint analysis in both Phase 3 trials reported observed differences in the QoL survey scores compared to placebo.
  • Sub-population Analysis

    • In a sub-analysis, studies evaluated the use of Compound X in patients with moderate Condition B.
  • Combination Therapies

    • Combination studies investigated whether adding Compound X to Treatment Z altered the observed effect.
    • This research is preliminary, and the need for further, larger studies is being explored.

Key Studies & References

  1. Pivotal Phase 3 Trial: Efficacy and Tolerability of Compound X in Chronic Condition A Pain Management
  2. Preliminary Investigation into the Combined Use of Compound X and Treatment Z: A Phase 2 Study

Frequently Asked Questions (FAQ)

Common questions about Diazolin (FAQ)


Q: Is Diazolin the same as Brand X or Drug Y?

Diazolin is the trade designation for the active therapeutic ingredient called Mebhydrolin, specifically Mebhydrolin napadisilate. Depending on the country, the same active compound may be marketed under different common international trade names, such as Omeril or Fabahistin. These different names refer to the same core medicine.


Q: Can Diazolin be taken at the same time as cold and flu medicine?

Official product information advises caution regarding the use of this medicine with other agents that cause CNS depression or have anticholinergic effects. Combining these medicines may result in additive effects, which regulatory documents note can include increased drowsiness and dry mouth.


Q: What kind of common food or drinks should be avoided while using Diazolin?

Official documentation describes a restriction on the use of alcohol (ethanol) during administration of this medicine. Alcohol is described as enhancing the sedative effects of Diazolin, potentially increasing drowsiness or impacting alertness.


Q: Does taking Diazolin affect the results of allergy skin tests?

As a first-generation antihistamine, official medical guidelines commonly include a recommendation that antihistamines, due to their mechanism of action, are temporarily discontinued before such testing. Because the drug blocks the body’s natural reaction to histamines, it can interfere with the results of allergy skin prick tests.


Q: Are there any official restrictions on using Diazolin while driving?

Official warnings state that the medicine may cause drowsiness or sedation, which can impair full mental alertness and coordination. Activities requiring full mental alertness, such as driving or operating heavy machinery, may be impacted if a patient experiences these effects.


Q: Why does Diazolin sometimes cause a dry mouth?

Dry mouth is a commonly reported effect linked to this medicine. This is due to its classification as a first-generation antihistamine, which means it possesses anticholinergic activity. This property is described as blocking certain chemical signals in the body, which can interfere with the processes that regulate saliva production.


Q: Is Diazolin a steroid or does it contain steroids?

According to the official product information, Diazolin is classified as a First-Generation Antihistamine and a Histamine H1-Receptor Antagonist. It is defined as a synthetic chemical compound and does not belong to the steroid class of drugs.


Q: Can Diazolin be used for motion sickness?

The official indication for this medicine is strictly for the symptomatic relief of allergic manifestations, such as skin conditions (e.g., urticaria) and rhinitis. Regulatory documents do not list motion sickness as an approved use for Diazolin.


Q: Is Diazolin only for seasonal allergies, or can it treat year-round symptoms?

The official indication is broadly described as the symptomatic relief of allergic symptoms and allergic dermatosis (skin conditions). This description implies the ability to manage various allergies, including those that are seasonal (acute) or year-round (perennial) manifestations.


Q: Does Diazolin interact with common over-the-counter pain relievers?

Official information indicates that the medicine can lead to an additive sedative effect when combined with other central nervous system (CNS) depressants. Combination medicines may contain ingredients that cause drowsiness, and regulatory information advises caution when co-administering CNS depressants.


Q: Can Diazolin affect sleep patterns or cause insomnia?

The most commonly reported effects in official documents are drowsiness and sedation, which may lead to excessive sleepiness. However, regulatory documents also note that paradoxical excitability and sleep disturbances, which is the opposite effect, can sometimes occur, particularly in children.


Q: What should a patient do if they accidentally take more Diazolin than intended?

Official patient information typically states that in the event of an accidental overdose or ingestion of too much medicine, the protocol involves immediately contacting a doctor, emergency medical services, or a Poison Control Center (or similar official authority) for guidance.


Q: What does it mean if an official document says Diazolin is 'contraindicated' for a certain group?

A contraindication is a critical safety term used in official documents to identify a condition or factor for which the use of a medicine is formally prohibited. The medicine is formally prohibited for use in patients who have a listed contraindication, such as closed-angle glaucoma or prostatic hyperplasia, as this may pose a risk of harm.


Q: Does Diazolin affect blood pressure readings?

Adverse reaction lists in official documents include cardiovascular effects, though not as a common reaction. Less common side effects reported may include changes in blood pressure, such as hypotension (low blood pressure).


Q: Can Diazolin be crushed or split for easier use?

The medicine is generally intended to be swallowed whole without chewing, as indicated in official administration guidelines. However, those same guidelines specifically permit the tablet to be crushed and mixed with food when the dose is being administered to young children.


Q: Can Diazolin interfere with birth control pills?

Regulatory documents state that Mebhydrolin is an inducer of hepatic microsomal enzymes. This mechanism means that co-administered medicines that are substrates for these enzymes, such as certain types of hormonal birth control, may experience reduced systemic exposure, as indicated in regulatory data.


Q: Are there official statistics on the frequency of common side effects of Diazolin?

Official documentation classifies side effects by their frequency (common, less common, or rare), based on clinical trial data. However, the patient-facing label typically uses these broad categories and does not usually provide specific numerical statistics or percentages for these classifications.


Q: Why is Diazolin not recommended for infants or very young children?

Regulatory documents explicitly prohibit the use of this medicine for newborns and infants. This prohibition is due to the potential for a heightened sensitivity in this age group to the adverse effects of antihistamines, particularly central nervous system effects like paradoxical excitability or respiratory depression.

How should Diazolin be stored and disposed of?

Official Storage and Disposal Instructions

Regulatory information defines strict requirements for storing and disposing of Diazolin (Mebhydrolin) to ensure product stability and safety.

Storage Conditions

Feature Requirement
Temperature Store at a temperature not exceeding 25 degree C.
Protection Store in a dry place and a place protected from light.
Containment Keep the medicine in its original packaging.
Access Must be stored out of reach of children.

Stability and Disposal

The medicine must not be used after the expiration date printed on the packaging. Unused or expired Diazolin should be disposed of via official drug take-back programs where available. If a take-back option is unavailable, the medicine should be secured for household trash disposal according to general governmental guidelines for non-controlled pharmaceuticals, which often involves mixing it with an undesirable substance in a sealed container. The product must not be flushed down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diazolin found in:

A-Z Index: